SELLAS Life Sciences (SLS) Interest & Investment Income (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Interest & Investment Income of -$2.6 million for Q4 2013, down 130200.0% year-over-year from N/an in Q4 2012, and down 23.43% quarter-over-quarter from -$2.1 million in Q3 2013.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Interest & Investment Income (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Interest & Investment Income for 4 consecutive years, with -$2.6 million the latest figure, recorded in Q4 2013.
- In Q4 2013, Interest & Investment Income fell 130200.0% year-over-year to -$2.6 million; the TTM figure through Sep 2014 stood at -$4.7 million (down 362.1% YoY), while the FY2016 annual figure was -$3.5 million, down 361.58% from the prior year.
- Interest & Investment Income declined to -$2.6 million in Q4 2013 per SLS's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.0 million in Q1 2013 and bottomed at -$3.1 million in Q2 2013.
- Historically, Interest & Investment Income has averaged -$64692.3 across 4 years, with a median of -$2000.0 in 2011.
- On a YoY basis, Interest & Investment Income climbed as much as 44043.75% in 2013 and fell as far as 130200.0% in 2013.
- SELLAS Life Sciences' Interest & Investment Income stood at $3000.0 in 2010, then sank by 133.33% to -$1000.0 in 2011, then jumped by 300.0% to $2000.0 in 2012, then sank by 130200.0% to -$2.6 million in 2013.
- Business Quant data shows SLS's Interest & Investment Income at -$2.6 million in Q4 2013, -$2.1 million in Q3 2013, and -$3.1 million in Q2 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | SELLAS Life Sciences | 2.65 Bn | 2.65 Bn | - | 1.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Mn |
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 597,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Dec 31, 2014 | -1.11 Mn |
| Jun 30, 2014 | -491,000.00 |
| Dec 31, 2013 | -2.60 Mn |
| Sep 30, 2013 | -2.11 Mn |
| Jun 30, 2013 | -3.13 Mn |
| Mar 31, 2013 | 7.03 Mn |
| Dec 31, 2012 | 2.71 Mn |